The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 302 participants.
Also called NCT05719376
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 302 participants
- Sponsor
- Registry
-
NCT05719376
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05719376. Randomized; no masking; primary purpose treatment. Start 2023-02 (anticipated); primary completion 2026-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes
- Condition
- Kidney Failure, Chronic
- Intervention (Drug)
- Monofer (experimental)
- Intervention (Drug)
- control group
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct05719376- Content hash
e4cc9c4b1449c989439a668f4c87fd5a67ad685b629aafc54868dfebfb24385a